Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7793559 | PMC |
| http://dx.doi.org/10.1097/QAD.0000000000002727 | DOI Listing |
Publication Analysis
Top Keywords
hiv-associated neurodegenerative
4
neurodegenerative disorders
4
disorders extracellular
4
extracellular intracellular
4
intracellular mechanisms
4
hiv-associated
1
disorders
1
extracellular
1
intracellular
1
mechanisms
1
Similar Publications
Changes in cerebrospinal fluid proteins across the spectrum of untreated and treated chronic HIV-1 infection.
PLoS Pathog
September 2024
Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Article Synopsis
- Researchers used the Olink Explore 1536 platform to analyze 1,463 unique proteins in cerebrospinal fluid (CSF) from 303 samples, including uninfected controls and various groups of individuals with HIV-1 infection.
- The study found significant correlations between CSF proteins and HIV-1 RNA levels, as well as nerve damage markers, highlighting distinct patterns of protein changes associated with different stages of HIV-1 progression.
- Antiretroviral therapy was shown to lessen protein imbalances in the CSF, although levels didn’t always return to those of uninfected controls; a comprehensive dataset is available online for further research on HIV-1's effects on the CNS.
The impact of aging on HIV-1-related neurocognitive impairment.
Ageing Res Rev
December 2024
Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine, New York, NY 10065, USA. Electronic address:
Article Synopsis
- HIV-1-related neurocognitive impairment affects up to 50% of people living with HIV, even with effective antiretroviral therapy (cART), complicating treatment and understanding of its causes.
- Biological aging is identified as a possible factor in the development and progression of this impairment, especially as life expectancy for individuals on cART approaches that of those without HIV.
- The text aims to explore how aging and HIV-1 infection interact at the clinical and molecular levels, highlighting the need for a clearer understanding of these combined effects on neurocognitive health.
Article Synopsis
- Neurodegenerative diseases like Alzheimer’s and Parkinson’s affect many people and their families, with no current cures but ongoing research into new treatments that could slow down these diseases and improve patient health.
- AGATHA is an AI-powered tool designed to analyze vast amounts of biomedical literature, helping researchers identify potential new uses for existing FDA-approved drugs by uncovering hidden links between medications and health conditions.
- The tool uses advanced statistical methods to create a multidimensional representation of genes and diseases, allowing for efficient categorization and prediction of disease-related genes, specifically focusing on finding drugs that could be repurposed for treating dementia linked to neurodegenerative disorders.
Levetiracetam Prevents Neurophysiological Changes and Preserves Cognitive Function in the Human Immunodeficiency Virus (HIV)-1 Transactivator of Transcription Transgenic Mouse Model of HIV-Associated Neurocognitive Disorder.
J Pharmacol Exp Ther
September 2024
Department of Pharmacology, University of Minnesota Medical School, Minneapolis, Minnesota (A.N.E., A.P., S.M.G., S.A.T.); and Department of Neuroscience, University of Minnesota, Minneapolis, Minnesota (S.D.H., C.K.-M., E.K.-M.)
Article Synopsis
- Nearly half of the 39 million people living with HIV are affected by HIV-associated neurocognitive disorder (HAND), which includes symptoms ranging from cognitive impairment to dementia, and currently has no established treatment.
- The HIV protein TAT is believed to contribute to HAND by causing neurotoxicity and resulting in network hyperexcitability that correlates with cognitive decline.
- The study demonstrates that the antiepileptic drug levetiracetam (LEV) can alleviate excitatory synaptic transmission issues and cognitive deficits in mice expressing the TAT protein, suggesting LEV might be a potential treatment for HAND.
Comprehensive Analysis of Dementia Types and Risk Factors: A Study From a Tertiary Care Center in India.
Cureus
June 2024
Internal Medicine, Dr. D. Y. Patil Medical College, Hospital and Research Centre, Dr. D. Y. Patil Vidyapeeth (Deemed to be University) Pune, Pune, IND.
Article Synopsis
- * Conducted between February 2022 and January 2024, the study included 81 patients aged 18 and older and diagnosed based on DSM-V criteria along with cognitive assessments; most participants were over 60 years old, with a predominance of females.
- * Alzheimer's disease emerged as the most common type of dementia (34.5%), followed by vascular and mixed dementia, while several reversible factors such as alcohol and hypothyroid associations were also noted among the cases.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!